Results 91 to 100 of about 21,798 (199)

Allele burden expansion in JAK2V617F and CALR‐mutated myeloproliferative neoplasms predicts disease progression and is associated with anagrelide treatment

HemaSphere, Volume 10, Issue 9, September 2026.
Zi Yun Ng, Laurane Cottin, Marine Demoy, Damien Luque Paz, Corentin Orvain, Wayne‐Corentin Lambert, Jean‐Christophe Ianotto, Eric Lippert, David M. Ross, Diana Iarossi, Alesia Khan, Daniel Lock, Catherine Truong, Kamel Laribi, Yun Fan Yang, Laura Li Gagnon, Valerie Ugo, Claire N. Harrison, Jennifer O'Sullivan   +18 more
wiley   +1 more source

Profile of pomalidomide and its potential in the treatment of myelofibrosis

Therapeutics and Clinical Risk Management, 2015
Krisstina L Gowin, Ruben A Mesa Division of Hematology and Medical Oncology, Mayo Clinic Arizona, Scottsdale, AZ, USA Abstract: Myelofibrosis, a Philadelphia-negative myeloproliferative neoplasm, is in a new treatment era after the discovery of ...
Gowin KL, Mesa RA
doaj  

Successful Management of Lupus‐Associated Autoimmune Myelofibrosis with Tofacitinib: A Case Report

ACR Open Rheumatology
We report a case of a 34‐year‐old woman with systemic lupus erythematosus (SLE) who developed thrombocytopenia and was diagnosed with lupus‐associated autoimmune myelofibrosis.
Hamidreza Soltani, Ali Dehghan
doaj   +1 more source

Effect of anemia developed after ruxolitinib initiation on adverse outcomes in patients with myelofibrosis: a nationwide cohort study. [PDF]

Blood Cancer J
Jeon M, Lee Y, Woo J, Kim JH, Shin JY.
europepmc   +1 more source

Type 1 CALR mutation allele frequency correlates with CD34/CXCR4 expression in myelofibrosis-type megakaryocyte dysplasia: A mechanism of disease progression?

Blood Cancer Journal
Giovanni Barosi, Rita Campanelli, Paolo Catarsi, Carlotta Abbà, Adriana Carolei, Margherita Massa, Robert Peter Gale, Vittorio Rosti   +7 more
doaj   +1 more source

Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study. [PDF]

Oncologist
Kiladjian JJ, Borate U, Abruzzese E, De Stefano V, Gong T, Breccia M, Palandri F, Pane F, Patriarca A, Reikvam H, Rein L, Yacoub A, Zhou F, Stouffs M, Assad A, Vannucchi AM.   +15 more
europepmc   +1 more source

Prognostic Scores and Risk Stratification of Myeloproliferative Neoplasms: 2026 Updates. [PDF]

Cancers (Basel)
Al-Zubaidi N, Ruiz E, Curto-Garcia N, Sriskandarajah P.   +3 more
europepmc   +1 more source

Describing the use of ruxolitinib for the treatment of myelofibrosis: a plain language summary of the ROMEI early study results. [PDF]

Future Oncol
Breccia M, Guglielmelli P, Castiglioni C, Palandri F, Passamonti F.   +4 more
europepmc   +1 more source

TP53 Mutations Unfavorably Impact the Outcomes of Myelofibrosis Patients with or Without Hematopoietic Stem Cell Transplantation: A Single-Center Study and Meta-Analysis. [PDF]

Int J Mol Sci
Frioni F, Giammarco S, Ceglie S, Betti S, Ramundo F, Marra J, Rossi M, Fosso F, Minnella G, Metafuni E, Sorà F, Bacigalupo A, Sica S, Rossi E, De Stefano V, Chiusolo P.   +15 more
europepmc   +1 more source

Allogeneic stem cell transplantation for myelofibrosis in the modern era: Single-center outcomes with DIPSS risk stratification. [PDF]

Blood Res
Choi DH, Jang JH, Jung CW.
europepmc   +1 more source